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antipsychotic treatment. METHODS: A naturalistic, prospective
cohort study, named COMETA, was conducted in 2006–2008.
Subjects aged 18–40 years, diagnosed with schizophrenia or
schizophreniform disorder 10 years before, were enrolled in 86
psychiatric centres throughout Italy and followed-up for a target
period of 52 weeks. Data on socio-demographic, clinical status,
adherence, HRQoL, resources consumption were collected (soci-
etal perspective adopted to estimate costs). RESULTS: A total of
637 valid patients (mean  SD age = 30.9  5.9, 65.0% male)
were enrolled and followed-up to 63.9 weeks. At enrolment,
the Positive-and-Negative-Syndrome-Scale (PANSS) mean  SD
score was 86.6  27.4, the Clinical-Global-Impression-Severity
(CGI-S) mean  SD score was 4.3  1.1, the Global-Assessment-
of-Functioning (GAF) mean  SD score was 54.1  13.8. With
EQ-5D 68.8% of patients reported moderate/severe anxiety/
depression, 52.7% reported problems with usual activities,
37.8% reported pain/discomfort, 21.4% had problems with
mobility, 16.7% problems with self-care, VAS mean  SD =
63.5  17.9. SF-36-PCS mean  SD = 47.59.3, SF-36-MCS
mean  SD = 39.0  9.6. During 90 days before enrolment,
1.9% patients did not take any antipsychotic drug, while 27%
took 2–5 different drugs. The Drug-Inventory-Attitude (DAI-30)
mean  SD score, assessing the patients’ subjective attitude
toward antipsychotic therapy, was 43.4  5.0. Physicians
reported that 71.1% patients always took the prescribed antipsy-
chotic therapy. Eighty-ﬁve percent of medical costs occurring 90
days before enrolment were: €114.00/patient-month for psycho-
therapy, €105.75/patient-month for hospitalizations (€89.49€ for
relapse), €86.37/patient-month for antipsychotics, €13.74 for
concomitant drugs. The patients persisted to treatment with oral
typical, atypical or long acting/depot drugs on average 53.9
weeks. During the follow-up, psychotherapy cost was 100.03€/
patient-month, hospitalizations cost €57.26/patient-month,
antipsychotic drug therapy cost €126.10, concomitant therapy
cost €16.47/patient-month. At the end of follow-up the patients’
clinical status, HRQoL and attitude toward treatment was on
average improved. CONCLUSIONS: Increase of adherence and
persistence toward antipsychotic treatment is a primary goal to be
reached for the improvement of well being in schizophrenic
patients and for making more efﬁcient investments.
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Almost 75% of schizophrenia patients do not comply with their
prescribed treatment leading to high relapse rates. Patient cen-
tered care (PCC) incorporates patient priorities into treatment
decisions, and has been proposed as a means to enhance compli-
ance and improve health outcomes among patients with schizo-
phrenia. PCC requires that patient objectives, priorities, and
desired outcomes be quantiﬁed and incorporated into treatment
decisions. Patient priorities for the treatment of schizophrenia
have not been evaluated. OBJECTIVES: To identify the spectrum
of patient objectives and priorities associated with the treatment
of schizophrenia. METHODS: Data was collected across
Germany in two stages: focus groups (n = 30) and individual
in-depth patient interviews (n = 25). Patients were eligible for
inclusion if they had been diagnosed with schizophrenia had
undergone treatment with an antipsychotic medication for at
least one year and, their disease was stable. The focus group
interviews were used to identify key attributes. These key
attributes were then quantiﬁed by a card sort exercise in indi-
vidual interviews. Results were analyzed using modiﬁed version
of the Borda Count on a scale from 0 to 100 and validated by
triangulation methods. RESULTS: Focus group interviews iden-
tiﬁed 13 objectives of primary importance to the patient. The
card sorting exercise during the in-depth interviews yielded the
top ﬁve attributes: therapeutic minimization of symptoms
(75.43), ability to concentrate/ think clearly (75.34), ability to
participate in social activities (69.93), alliance with physician
(66.19), and avoiding acute symptoms (62.62). The scores
ranged from 29.42 to 74.43 out of a possible 100 points. CON-
CLUSIONS: Traditionally, treatment for schizophrenia has
focused on remission of symptoms; however, patient’s top pri-
orities involve the processes of care. Addressing patient’s priori-
ties and improving the entire treatment pathway will likely lead
to increased compliance with treatments and ultimately improve
clinical outcomes.
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OBJECTIVES: The purpose of this study was to estimate the
direct cost of treating patients with schizophrenia in Greece,
based on 12-month retrospective data collected at baseline from
e-STAR. METHODS: e-STAR is an ongoing, international, pro-
spective, observational study of clinical and economic outcomes
in schizophrenic patients who switch to a new antipsychotic.
e-STAR captures real-life data both in the inpatient and outpa-
tient settings based on a systemic data collection form via a
secured web-based system. At baseline, psychiatric-related
resource utilisation, such as hospitalisation, community care,
visits to health care professionals, diagnostic procedures and
use of medication, was retrospectively collected for the previous
12 months. Unit costs were derived from published literature,
price lists of social insurance funds, the Greek NHS and the
private sector. RESULTS: Data from 798 patients (57.5% male)
who were enrolled in e-STAR in Greece and diagnosed with
schizophrenia were analysed. The mean age of the study popu-
lation was 39.5 years and the mean time since diagnosis was 12.4
years. Analysis of resource utilization data indicated that total
length of stay in public psychiatric hospitals was 2.7 times higher
than that in private clinics. Outpatient care mainly consisted of
visits to psychiatrists, whereas visits to other relevant health care
professionals were very low. Finally, the total annual cost per
patient with schizophrenia was estimated at €3729, of which
64.5% referred to hospital and community care, 18.5% to out-
patient care, 6.0% to diagnostic procedures and only 11.0% to
medication. CONCLUSIONS: This is the ﬁrst time that large-
scale Greek real-life data are used in the ﬁeld of the economics of
schizophrenia in Greece. The results of this study are in general
agreement with ﬁndings of previous studies conducted in Greece
and Europe. Further research needs to be undertaken in this ﬁeld
when long-term prospective data become available from e-STAR.
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